Trump’s attorneys issue a powerful response to the

New Post Public Reply Private Reply Replies (1) Message Board
PoemStone
240
Trump’s attorneys issue a powerful response to the Articles of Impeachment
By Andrea Widburg < >

Anyone who has watched a Trump rally or followed Trump’s Twitter feed knows that he’s been open about his disdain for the House’s impeachment proceedings. However, now that the House formally delivered the Articles of Impeachment to the Senate, Trump’s lawyers can finally make known the President’s official legal stand against the Democrats’ blatant political effort to overturn the 2016 election.

In five-and-a-half fiery pages, Jay Alan Sekulow and Pat A. Cipollone attack both the impeachment process and the legal and factual bases (or lack thereof) underlying the articles of impeachment. Sekulow and Cipollone understand that the real audience is the American people, so the document is written in ordinary English, not legalese.

Regarding the entire impeachment, the lawyers state that this warped process attacks the American people and free elections:

The Articles of Impeachment submitted by House Democrats are a dangerous attack on the right of the American people to freely choose their President. This is a brazen and unlawful attempt to overturn the results of the 2016 election and interfere with the 2020 election-now just months away. The highly partisan and reckless obsession with impeaching the President began the day he was inaugurated and continues to this day.

For the first Article of Impeachment, which alleges “abuse of power,” Sekulow and Cipollone explain that, contrary to the Constitution’s demand for “high Crimes and Misdemeanors,” the first Article fails to state any legal violation. Not only does it fail to identify actual legal wrongdoing, the facts alleged also fail to show that Trump abused his powers:

At all times, the President has faithfully and effectively executed the duties of his Office on behalf of the American people. The President's actions on the July 25,2019, telephone call with President Volodymyr Zelenskyy of Ukraine (the "July 25 call" , as well as on the earlier April 21, 2019, telephone call (the "April 21 call" , and in all surrounding and related events, were constitutional, perfectly legal, completely appropriate, and taken in furtherance of our national interest.

The attorneys also note that the best evidence is the telephone call transcript, which Trump released immediately. Ukrainian officials, from President Zelenskyy on down, all support the transcript and the tenor of Trump’s deals with Ukraine.

Additionally, Gordon Sondland, Ambassador to the European Union, testified that Trump disavowed any quid pro quo, as did Senator Ron Johnson. It was only a “fundamentally flawed and illegitimate process” that let the House Democrats turn undisputed facts and legitimate constitutional powers into an article that is “constitutionally invalid, founded on falsehoods, and must be rejected.”

Sekulow and Cipollone make equally short shrift of the Second Article for obstruction of Congress. Trump was within the purview of his constitutional powers and, indeed, “acted with extraordinary and unprecedented transparency by declassifying and releasing the transcript of the July 25 call that is at the heart of this matter.”

Instead, it was the House Democrats who abused their powers by issuing “a series of unconstitutional subpoenas for documents and testimony,” something they did without the necessary predicate of a congressional vote. In addition, although they don’t use the word, the attorneys state facts describing the kangaroo court proceedings in which the House Democrats engaged.

What the House Democrats did, say the attorneys, was to violate the Constitution from root to branch by trying to disenfranchise American voters and take control of Executive powers:

In the first Article, the House attempts to seize the President's power under Article II of the Constitution to determine foreign policy. In the second Article, the House attempts to control and penalize the assertion of the Executive Branch’s constitutional privileges, while simultaneously seeking to destroy the Framers’ system of checks and balances. By approving the Articles, the House violated our constitutional order, illegally abused its power of impeachment, and attempted to obstruct President Trump's ability to faithfully execute the duties of his Office. They sought to undermine his authority under Article II of the Constitution, which vests the entirety of “ he executive Power” in “a President of the United States of America.”

There is nothing more to add. Sekulow and Cipillone are correct in every respect.
1
Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 43

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 47

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 38

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 44

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 38

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 35

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Launched into AppLovin Corporation's Alleged Fraud

Updated Category News Views 386

Investigation into AppLovin Corporation In recent news, a substantial class action lawsuit has emerged against AppLovin Corporation (NASDAQ: APP). This national law firm, known for advocating for investors, aims to hold the company accountable for alleged securities law violations. Understanding the Class Action Lawsuit This lawsuit pertains to any individuals or entities...

Continue Reading
Safe Harbor Financial Expands Support for Cannabis Operators

Updated Category News Views 33

Safe Harbor Financial Takes Bold Step in Cannabis Financing In a remarkable move, Safe Harbor Financial has successfully arranged a secured credit facility valued at $1.07 million. This milestone supports a cannabis operator, marking a significant step in bolstering financial services within the cannabis industry. With their expertise in facilitating innovative financial...

Continue Reading
Nidec Corporation Faces Securities Investigation: Key Insights

Updated Category News Views 224

Understanding Nidec Corporation's Current Challenges Nidec Corporation is undergoing scrutiny due to serious allegations in its business practices. This Japanese manufacturer, known for its electronic components, faces potential claims of issuing misleading information to its investors. Recent developments have raised questions about its transparency and accountability in...

Continue Reading
Understanding HCI Group's Short Interest Trends and Insights

Updated Category News Views 126

An Overview of HCI Group's Short Interest HCI Group's short interest has sparked interest among traders and investors alike, showing a recent increase of 7.38% from the previous report. This shift indicates that there are currently around 404 thousand shares sold short, comprising 4.95% of the company’s total tradable shares. Observing the trading volume, it has been...

Continue Reading
Fresenius Kabi Introduces New Epinephrine Injection for Patients

Updated Category News Views 151

Fresenius Kabi Launches Epinephrine Injection, USP Fresenius Kabi, a proud branch of the Fresenius organization, has taken a significant step in enhancing its pharmaceutical portfolio in the United States by making available Epinephrine Injection, USP. This launch positions Fresenius Kabi at the forefront as it becomes the first company to offer a generic 1mg/1mL vial of...

Continue Reading